Physician profile
Mark Josephson
NPI 1649223470
$4,519.77
in general payments reported to CMS, 2019-2025
29 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,632 · 2020: $918 · 2021: $1,093 · 2022: $281 · 2023: $250 · 2024: $111 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $707.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.31 | 2019-2023 | Jardiance |
| Pfizer INC. | $404.94 | 2019-2021 | |
| Novo Nordisk INC | $383.12 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $316.06 | 2019-2021 | |
| Lilly USA, LLC | $300.99 | 2019-2021 | |
| Abbott Laboratories | $299.62 | 2020-2024 | Mitraclip |
| Glaxosmithkline, LLC. | $252.51 | 2019-2022 | |
| Amarin Pharma, INC. | $172.36 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $147.41 | 2019-2025 | Gardasil 9, Capvaxive, Vaqta |
| Intuitive Surgical, INC. | $128.00 | 2025 | |
| Edwards Lifesciences Corporation | $125.00 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astellas Pharma US INC | $115.27 | 2019 | |
| Horizon Therapeutics Plc | $99.33 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $92.21 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $64.65 | 2019-2021 | |
| Neotract INC. | $63.61 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $48.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $47.81 | 2019 | |
| Allergan, INC. | $45.30 | 2019 | |
| Arthrex, INC. | $45.00 | 2019 | |
| Esperion Therapeutics, INC. | $30.76 | 2021 | |
| Harmony Biosciences LLC | $28.90 | 2020 | |
| Alnylam Pharmaceuticals INC. | $23.67 | 2021 | |
| Scilex Pharmaceuticals INC. | $23.09 | 2019 | |
| Eisai INC. | $20.59 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.14 | 2021 | |
| Ibsa Pharma INC. | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Josephson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.